Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева. 2 ГБОУ ВПО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310. 3 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1.
Список исп. литературыСкрыть список 1. Беккер Р.А., Быков Ю.В., Морозов П.В. Выдающиеся психиатры ХХ века. — М.: ИД «Городец»; 2019. 2. Пятницкий Н.Ю. «Первичные», «основные» и «вторичные» симптомы шизофрении в концепции Е. Блёйлера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017; 117 (8): 88–97. 3. Andreasen NC. Methods for Assessing Positive and Negative Symptoms. Mod Probl Pharmacopsychiatry. 1990;24:73-88. 4. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations. Br J Psychiatry Suppl. 1989;(7):49-58. 5. Barnes TR, Leeson VC, Mutsatsa SH et al. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 2008;193:203-209. 6. Bellack AS, Morrison RL, Wixted JT, Mueser KT. An analysis of social competence in schizophrenia. Br J Psychiatry. 1990;156:809-818. 7. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull. 2006;32(Suppl 1):S44-S63. 8. Debelle M, Németh G, Szalai E et al. Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial. European Neuropsychopharmacology. 2015(25):S510. 9. Dodell-Feder D, Tully LM, Hooker CI. Social impairment in schizophrenia: new approaches for treating a persistent problem. Curr Opin Psychiatry. 2015;28(3):236-242. 10. Drake RE, Bond GR, Ben-Zeev D. Psychiatric Rehabilitation in Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 11. Frye RE. Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents. CNS Drugs. 2018;32(8):713-734. 12. Harvey PD, Bowie CR. Cognitive enhancement in schizophrenia: Pharmacological and Cognitive Remediation Approaches. Psychiatric Clin North Am. 2012;35:683-698. 13. Harvey PD, Keefe RS, Eesley CE. Neurocognition in Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 14. Hegarty JD, Baldessarini RJ, Tohen M et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409-1416. 15. Hooley JM. Social factors in schizophrenia. Curr Direct Psychol Sci. 2010;19:238-242. 16. Ivleva EI, Tamminga CA. Psychosis as a Defining Dimension in Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 17. Jonsdottir A, Waghorn G. Psychiatric disorders and labour force activity. Ment Health Rev Jr 2015;20:13. 18. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry. 2008;21(6):630-639. 19. Kane JM, Correll CU. Schizophrenia: Pharmacological Treatment. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 20. Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633-647. 21. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30:279-293. 22. Koivumaa-Honkanen HT, Viinamäki H et al. Correlates of life satisfaction among psychiatric patients. Acta Psychiatr Scand. 1996;94(5):372-378. 23. Kozma C, Dirani R, Canuso C, Mao L. Change in employment status over 52 weeks in patients with schizophrenia: an observational study. Curr Med Res Opin. 2011;27:327-333. 24. Lewis SF, Escalona R, Keith SJ. Phenomenology of Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 25. Lezenweger MF, Dworkin RH. The dimensions of schizophrenia phenomenology. Not one or two, at least three, perhaps four. Br J Psychiatry. 1996;168:432-440. 26. Lieberman JA, Drake RE, Sederer LI et al. Science and recovery in schizophrenia. Psychiatr Serv. 2008;59(5):487-496. 27. Malm U, May P, Dencker S. Evaluation of the quality of life in schizophrenic outpatients: A checklist. Schizophr Bull. 2001;7:477-486. 28. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10:23-41. 29. Mier D, Kirsch P. Social-Cognitive Deficits in Schizophrenia. Curr Top Behav Neurosci. 2017;30:397-409. 30. Millan MJ. [Dopamine D3 receptors as a novel target for improving the treatment of schizophrenia]. [Article in French]. Med Sci (Paris). 2005;21(4):434-442. 31. Moll MF, Saeki T. Social life of people with diagnosis of schizophrenia, attended at a psychosocial care center. Rev Lat Am Enfermagem. 2009;17(6):995-1000. 32. Nasrallah HA, Targum SD, Tandon R et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv. 2005;56(3):273-282. 33. Neill JC, Grayson B, Kiss B et al. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26(1):3-14. 34. Németh B, Molnár A, Akehurst R et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017;6(8):639-648. 35. Nemeth G, Debelle M, Laszlovszky I et al. Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: a double-blind, active comparator-controlled trial. European Psychiatry. 2016;33:S303. 36. Németh G, Laszlovszky I, Czobor P et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. The Lancet. 2017;389(10074):1103-1113. 37. Perez JM, Ghose S. Cellular and Molecular Neuropathology of Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 38. Priebe S. Social outcomes in schizophrenia. Br J Psychiatry Suppl. 2007;50:s15-20. 39. Robertson BR, Prestia D, Twamley EW et al. Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia. Schizophr Res. 2014;160(1-3):136-141. 40. Saarni SI, Viertiö S, Perälä J et al. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. Br J Psychiatry. 2010;197:386-394. 41. Salokangas RK, Honkonen T, Stengård E, Koivisto AM. Subjective life satisfaction and living situations of persons in Finland with long-term schizophrenia. Psychiatr Serv. 2006;57(3):373-381. 42. Souetre E. Economic evaluation in schizophrenia. Neuropsychobiology. 1997;35:67-69. 43. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. 4th Ed. 2013. ISBN 978-1-107-68646-5. 44. Strauss JS, Carpenter WT, Bartko J. The diagnosis and understanding of schizophrenia. III. Speculations on the process that underlies schizophrenic symptoms. Schizophr Bull. 1974;11:61-75. 45. Suttajit S, Arunpongpaisal S, Srisurapanont M et al. Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains? Neuropsychiatr Dis Treat. 2015;11:2471-2477. 46. Suzuki T, Remington G, Mulsant BH et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012;197(1-2):1-6. 47. Swartz MS, Perkins DO, Stroup TS et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164:428-436. 48. Takeuchi S, Hida H, Uchida M et al. Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. Neurochem Int. 2019;128:127-134. 49. Tamminga CA. Schizophrenia: Introduction and Overview. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 50. Trauer T, Duckmanton RA, Chiu E. Estimation of costs of public psychiatric treatment. Psychiatr Serv. 1998;49:440-442. 51. Watson DJG, King MV, Gyertyán I et al. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016;26(2):208-224. 52. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: WHO Press; 2008. 53. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30:196-205.